|Meeting Room 1.41 - 1.42||Meeting Room 1.43 - 1.44||Meeting Room 1.61 - 1.62||Meeting Room 1.63 - 1.64||Offsite
The Southern Sun, Cape Sun
|Break | 10:30 - 12:00|
|Lunch | 12:30 - 13:30||Lunch | 12:30 - 13:30|
|Break | 14:00 - 14:30|
|Meeting Room 1.61 - 1.62||Meeting Room 1.63 - 1.64||Roof Terrace Room|
Monday 27 October
Preventing Cell-associated HIV Transmission with Antibodies: Implications for PrEP and Vaccine Development
Session Chairs: Deborah Anderson and Roger LeGrand
Host Institution: International AIDS Vaccine Initiative
Session Chair: Jill Gilmour
Studies of early HIV infection with longitudinal follow-up have contributed in many ways to our understanding of the epidemic: clinical course of infection, risk factors, potential public health/behavioral or structural interventions, nature of transmitted viruses, interplay of host immune response and genetics with viral variation/escape, evolution of broadly neutralizing antibodies and others. This session will review the cohorts on which the work has been based and the key findings, with an emphasis on insights for vaccine design and value for other prevention methods. The participants will be asked to provide brief descriptions of cohorts and available specimens and to describe the key research questions addressed and major findings. Cohort studies and immune correlates of protection in the context of superinfection may also be included. Discussion will focus on remaining questions, potential collaborations and what additional clinical studies are required to resolve remaining scientific questions and improve public health.
Host Institutions: AMAG, AVAC, GYCA, IRMA, International HIV/AIDS Alliance, NHVMAS, Sonke Gender Justice, Siyaifuna, Southern African AIDS Trust, World AIDS Campaign
Session Chairs: Manju Chatani, Sydney Hushie, Rosemary Mburu and Ntando Yola
The current HIV prevention landscape offers new opportunities and challenges to advocates interested in biomedical HIV prevention R&D as well as implementation of positive results into policies and programs. International, African and South African civil society partners will hold this workshop to equip advocates, new investigators, community liaison officers and other stakeholders to more fully participate in biomedical HIV prevention research and HIVR4P. The workshop will provide an overview of the field to contextualize themes/issues at HIVR4P; connect research and advocacy priorities and explore common goals; and build capacity of advocates and trial staff to better engage with emerging issues. More information at www.avac.org/hivr4p
As capacity is limited, please register here to reserve a place https://www.surveymonkey.com/s/QHRJ6F8
Have you ever used PrEP, now or in the past? If so, we would love to hear from you!
As part of the Advocates’ Pre-Conference Workshop, we are organizing a panel of PrEP users to speak about our lived experience. We are looking for PrEP users from a variety of backgrounds and experiences, including diversity in terms of gender, age, ethnicity, sexual orientation, different regions of the world, in serodiscordant relationships, single and sexually active, using drugs, sex worker, trying to conceive (PrEP-ception), current and former PrEP study participants… If you will be in Cape Town at the end of October, please let me know! Please contact me directly at firstname.lastname@example.org if you are interested. And please share this information with any individuals who might be interested, as well as through any networks or listservs that might reach PrEP users attending the HIV R4P Conference.
Host Institution: US Military HIV Research Program
Session Chair: Nelson Michael
Conducting HIV research in the care and treatment setting directly integrates scientific inquiry with service delivery. Such investigation informs global health programs including those supported by the President's Emergency Plan for AIDS Relief. Within its international network, the U.S. Military HIV Research Program (MHRP) recognizes the opportunities afforded by leveraging traditional clinical research and implementation science. Engaging collaborators and colleagues in the field, this session will highlight ongoing PEPFAR prevention research efforts in key populations and define challenges to addressing critical evidence gaps. Highlighted research will include cost-effectiveness analysis in PMTCT delivery models in Kenya, uptake of treatment as prevention by MSM in trusted community centers in Nigeria, and a long-term cohort study evaluating prevention outcomes in Kenya, Tanzania, Nigeria, and Uganda.
Addressing Regulatory Challenges Associated with HIV Vaccine Trials in the Evolving World of Standards for Treatment and Prevention
Session Chairs: Representatives from National Regulatory Agencies
Mind the Gaps – Economic, Programmatic and Human Dimensions of Access to Future AIDS Vaccines and Their Importance for Decision-Making in R&D
Session Chairs: Alex Coutinho and Glenda Gray
Session Chair: Blake Ball
Session Chair: Gustavo Doncel
Session Chairs: Linda-Gail Bekker and Margie McGlynn
AIDS vaccine and cure researchers have long been riddled by HIV's unparalleled challenges: its rapid mutation and enormous global variability, lifelong persistent infection, direct targeting of immune cells and lack of correlates and predictive animal models to predict efficacy in humans. Increased understanding of the immune responses that prevent or control infection and of how anti-retroviral treatment controls HIV, the advent of new technologies and recent breakthroughs have renewed optimism and confidence for both vaccines and cure. Scientists are finding close associations between approaches to prevent infection and those to control viral replication and transmission. Broadly neutralizing antibodies (bnAbs) capable of preventing infection had a strong therapeutic effect when passively administered to SHIV-infected monkeys, reducing viral load to undetectable levels. And a vaccine candidate aimed at inducing T-cell responses in monkeys controlled SIV infection to undetectable levels, suggesting that cellular immune responses could also be beneficial prophylactically and therapeutically. New insights into the induction and role of bnAbs, T-cell responses and immune-based therapies are proving crucial in both vaccine and cure research.
Friday 31 October
Session Chairs: José Fernández-Romero and Manjula Lusti-Narasimhan
This session explores the impact of key STIs; their role in increasing susceptibility to HIV; new biomedical prevention approaches including topical microbicides and multi-purpose prevention technologies (MPTs); and the scientific and regulatory hurdles that must be overcome to make combination HIV/STI prevention a reality.
Session Chairs: Glenda Gray, Stacey Hannah, Catherine Slack, and Ntando Yola
What Can We Learn from Innovative Interventions to Increase the Uptake of Voluntary Medical Male Circumcision in Eastern and Southern African Countries?
Session Chair: Annette N. Brown
The evidence will include findings from four different impact evaluation studies aiming to increase the uptake of VMMC using various types of interventions. The interventions include a sport-based intervention, two behavior change communication interventions (with one using mobile technology), and an intervention that uses behavioral economics by compensating men for opportunity costs resulting from undergoing VMMC. The presentations and discussions between researchers and program implementers in this session will highlight synergies and differences between findings.